Biopharma covers demand of the domestic market for blood products by 100%, it can resume their export, Oksana Muliarchuk, director of the company’s plasma center network, has said.
“The need for blood products is now 100% closed, we are closing the need for all hospitals, including military ones,” she told Interfax-Ukraine.
Muliarchuk explained that the need for such drugs has decreased since the beginning of the war, in particular due to the fact that a significant part of cancer patients who need such drugs have gone abroad.
At the same time, she noted that the Ministry of Health constantly monitors the availability of stocks of blood products in warehouses.
In addition, according to Maliarchuk, Biopharma began to restore the work of its plasma centers. So, for two months since the beginning of the war, plasma centers in Cherkasy and Sumy had been operating, which prepared only blood components, and in early May, the company resumed the work of plasma collection centers in Cherkasy and Kamianske, and is launching the center in Sumy.
“Unfortunately, we have centers where we cannot resume work yet. For example, in Kharkiv we cannot resume work due to hostilities. In Kyiv, the work of a plasma center has not been resumed for technical reasons – we are waiting for the opportunity to equip a bomb shelter in the building where it is located,” she said.
As reported, the Cabinet of Ministers provided for the possibility of lifting a ban on the export of blood products until martial law is lifted on the basis of a reasonable submission from the Ministry of Health, subject to meeting the needs of the healthcare system in such drugs.
Earlier, the biopharmaceutical company Biopharma (Kyiv) announced plans to invest $20-23 million in the development of a network of plasma centers by 2025, build plasma centers and blood centers in every regional center of Ukraine.
